Oncolytics Biotech (TSE:ONC) Stock Crosses Above Two Hundred Day Moving Average – What’s Next?

Oncolytics Biotech Inc. (TSE:ONC)’s stock price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of C$14.90 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares trading hands.

Oncolytics Biotech Price Performance

The company has a debt-to-equity ratio of 14.58, a quick ratio of 8.86 and a current ratio of 2.88. The firm has a market cap of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80. The company’s fifty day moving average is C$14.90 and its two-hundred day moving average is C$14.90.

Insider Buying and Selling at Oncolytics Biotech

In other news, Director Patricia Andrews purchased 35,400 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The shares were purchased at an average price of C$1.18 per share, with a total value of C$41,772.00. Following the purchase, the director directly owned 78,128 shares of the company’s stock, valued at approximately C$92,191.04. This represents a 82.85% increase in their position. Also, insider Andrew P. Aromando purchased 29,600 shares of the company’s stock in a transaction that occurred on Wednesday, February 11th. The shares were purchased at an average cost of C$1.18 per share, for a total transaction of C$34,928.00. Following the purchase, the insider directly owned 55,100 shares in the company, valued at C$65,018. This trade represents a 116.08% increase in their ownership of the stock. In the last three months, insiders have acquired 289,232 shares of company stock worth $335,760. Corporate insiders own 3.82% of the company’s stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.